Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pirtobrutinib (LOXO-305) against investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab) in previously treated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Idelalisib (idelalisib)
• LOXO-305 (Pirtobrutinib) (pirtobrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-07